Centene Raises 2026 Guidance After Strong Q2, Board Refresh
CNC has more than doubled off its 52-week low of $25.075.
Summary
Centene reported Q2 adjusted EPS of $2.51, raised full-year adjusted EPS guidance to above $4.80, and announced board changes including the appointment of Paul Diaz.
Updates
· dpa-AFX — Shares rose 1.9% pre-market after the beat and raised outlook.
Key Events · Earnings and Guidance · CNC
-
Q2 Earnings Beat
Adjusted diluted EPS of $2.51 vs. a loss of $0.16 in Q2 2025; GAAP diluted EPS of $2.19 vs. a loss of $0.51. Total revenues rose to $53.6B.
-
Full-Year Guidance Raised
2026 adjusted diluted EPS guidance raised to >$4.80 (from prior implied ~$4.30 midpoint); total revenue guidance increased by $6B to $193.5B-$197.5B.
-
Health Benefits Ratio Improves
Consolidated HBR improved to 89.6% from 93.0% a year ago, driven by better pricing in Marketplace and Medicaid, and favorable Medicare development.
-
Board Refresh
Director Kenneth Burdick retired; Paul Diaz, a healthcare PE veteran and former CEO of Myriad Genetics and Kindred Healthcare, appointed to the Board.
Analysis · CNC · Finance
Centene delivered a strong Q2 with adjusted EPS of $2.51, beating the prior-year loss, and raised full-year guidance significantly — adjusted EPS now seen above $4.80 versus a prior implied range that was much lower. The HBR improved sharply to 89.6% from 93.0% a year ago, driven by better pricing and cost management across all segments. The board changes — a director retirement and the appointment of a healthcare PE veteran — add governance news but are not the main story. The guidance raise and operational turnaround are the key takeaways for investors.
How filings like this one have moved
In the 30 days to Oct 4, 2026, 36.7% of the 1012 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.64%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CNC was trading at $67.38 on NYSE in the Finance sector, with a market capitalization of approximately $31.6B. The 52-week trading range was $25.08 to $69.36. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.